CA
NZ
UK
AU
IND
US
…
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn's disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne. Further, it provides Vmonalisa, modified sodium hyaluronate filler for mid to deep dermal implantation; augentropfen stulln mono eye drops for asthenopia; EyeOP1 glaucoma treatment device; and Elcitonin for Osteoporosis pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 2048.79M | 2010.31M | 2873.77M | 3762.85M | 3456.59M |
| Minority interest | 45.62M | 6.71M | 16.51M | -17.20M | -7.86M |
| Net income | 1450.47M | 1619.79M | 2400.94M | 3258.99M | 3017.40M |
| Selling general administrative | 3708.03M | 780.09M | 656.63M | 636.61M | 441.00M |
| Selling and marketing expenses | - | 2661.65M | 2511.34M | 2721.31M | 2540.15M |
| Gross profit | 5720.02M | 5422.19M | 6075.95M | 7035.85M | 6246.94M |
| Reconciled depreciation | 266.93M | 259.24M | 229.56M | 227.23M | 219.82M |
| Ebit | 1537.75M | 2048.92M | 2712.85M | 3622.44M | 3377.56M |
| Ebitda | 1797.79M | 2308.16M | 2922.15M | 3849.67M | 3597.38M |
| Depreciation and amortization | 260.04M | 259.24M | 209.30M | 227.23M | 219.82M |
| Operating income | 1537.75M | 1732.51M | 2712.85M | 3622.44M | 3377.56M |
| Other operating expenses | 6462.39M | 5736.48M | 5300.44M | 5504.79M | 5121.09M |
| Interest expense | 19.77M | 38.61M | 46.25M | 49.09M | 28.27M |
| Tax provision | 659.78M | 397.23M | 489.34M | 486.65M | 431.32M |
| Interest income | 82.35M | 126.34M | 146.47M | 105.52M | 81.85M |
| Net interest income | 62.05M | 87.73M | 100.22M | 56.43M | 53.58M |
| Income tax expense | 642.76M | 397.23M | 489.34M | 486.65M | 431.32M |
| Total revenue | 8000.14M | 7468.99M | 8013.28M | 9150.35M | 8337.22M |
| Total operating expenses | 4182.27M | 3689.68M | 3363.10M | 3390.29M | 3030.81M |
| Cost of revenue | 2280.12M | 2046.80M | 1937.33M | 2114.50M | 2090.28M |
| Total other income expense net | 511.04M | 277.79M | 160.92M | 140.41M | 79.03M |
| Net income from continuing ops | 1443.28M | 1613.08M | 2384.43M | 3276.20M | 3025.26M |
| Net income applicable to common shares | - | - | - | 3258.99M | 3017.40M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 19208.55M | 18047.79M | 17730.84M | 17753.54M | 15807.88M |
| Intangible assets | 3696.30M | 3490.60M | 2216.09M | 3351.84M | 3006.18M |
| Other current assets | 261.36M | 210.17M | 149.72M | 253.77M | 213.12M |
| Total liab | 1656.93M | 1644.68M | 2174.43M | 3016.46M | 2960.89M |
| Total stockholder equity | 17404.52M | 16311.47M | 15520.21M | 14589.07M | 12752.44M |
| Other current liab | 682.45M | 331.56M | 305.05M | 899.95M | 814.67M |
| Common stock | 83.61M | 83.56M | 83.99M | 83.99M | 84.18M |
| Capital stock | 83.56M | 83.56M | 83.99M | 83.99M | 84.18M |
| Retained earnings | 14738.72M | 13959.01M | 13425.96M | - | 10550.09M |
| Other liab | - | - | - | 125.87M | 286.06M |
| Good will | 1512.02M | 1547.90M | 1547.90M | 1665.99M | 1691.18M |
| Other assets | 0.00M | - | - | 1354.42M | 903.66M |
| Cash | 2702.74M | 3706.50M | 4311.06M | 4376.38M | 3385.74M |
| Total current liabilities | 1469.97M | 1516.06M | 2048.79M | 2877.10M | 2081.25M |
| Current deferred revenue | 12.14M | - | 17.23M | 898.95M | 812.67M |
| Net debt | -2012.32M | -2845.76M | -3009.32M | -2563.74M | -1673.43M |
| Short term debt | 668.75M | 848.23M | 1285.07M | 1799.14M | 1120.68M |
| Short long term debt | 651.82M | 831.30M | 1269.65M | 1783.34M | 1103.76M |
| Short long term debt total | 690.43M | 860.74M | 1301.74M | 1812.63M | 1712.31M |
| Other stockholder equity | 17320.92M | 2268.90M | 2297.61M | 14505.08M | 12668.27M |
| Property plant equipment | - | - | - | 495.46M | 529.87M |
| Total current assets | 9303.27M | 8704.86M | 8794.43M | 8829.38M | 7379.72M |
| Net tangible assets | - | - | - | 10856.65M | 8845.57M |
| Short term investments | 3086.46M | 2160.10M | 1832.26M | 1491.34M | 977.87M |
| Net receivables | 2448.34M | 1859.95M | 1863.76M | 1442.04M | 2330.38M |
| Long term debt | - | - | - | 0.00M | 573.81M |
| Inventory | 804.36M | 768.14M | 637.64M | 477.21M | 472.60M |
| Accounts payable | 106.63M | 142.43M | 141.66M | 178.01M | 145.90M |
| Accumulated other comprehensive income | - | - | -287.36M | - | - |
| Non currrent assets other | 0.00M | 2262.32M | 2916.05M | 3042.67M | 2079.51M |
| Non current assets total | 9905.29M | 9342.93M | 8936.40M | 8924.16M | 8428.16M |
| Capital lease obligations | 38.26M | 29.44M | 32.09M | 29.30M | 34.73M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -693.82M | -615.10M | -442.28M | -1178.20M | -898.53M |
| Change to liabilities | - | - | - | 0.00M | -24.56M |
| Total cashflows from investing activities | -984.32M | -615.10M | -442.28M | -1178.20M | -1519.53M |
| Net borrowings | -179.49M | -442.85M | -510.19M | - | 1065.57M |
| Total cash from financing activities | -770.94M | -1261.05M | -2125.02M | -1399.91M | -258.39M |
| Change to operating activities | - | - | - | - | -112.77M |
| Net income | 2103.06M | 2010.31M | 2873.77M | 3762.85M | 3456.59M |
| Change in cash | -1005.12M | -604.56M | -65.32M | 990.64M | 717.31M |
| Begin period cash flow | 3706.50M | 4311.06M | 4376.38M | 3385.74M | 2668.43M |
| End period cash flow | 2701.38M | 3706.50M | 4311.06M | 4376.38M | 3385.74M |
| Total cash from operating activities | 758.42M | 1268.55M | 2502.85M | 3553.24M | 2493.85M |
| Depreciation | 266.93M | 259.24M | 229.56M | 227.23M | 219.82M |
| Other cashflows from investing activities | -167.30M | -178.68M | 66.50M | -554.70M | 126.64M |
| Dividends paid | 660.55M | 556.16M | 1360.36M | -1276.24M | -1154.83M |
| Change to inventory | -55.91M | -130.50M | -235.77M | 8.16M | -90.86M |
| Change to account receivables | -611.17M | -49.34M | 410.56M | - | -367.89M |
| Sale purchase of stock | 0.00M | -238.39M | 0.00M | -48.38M | -151.52M |
| Other cashflows from financing activities | 69.10M | -23.64M | -236.40M | 1352.70M | 1047.97M |
| Change to netincome | - | - | - | 67.03M | -147.30M |
| Capital expenditures | 514.41M | 455.91M | 317.96M | 524.92M | 184.84M |
| Change in working capital | -648.78M | -128.15M | 2.97M | 90.08M | -596.07M |
| Stock based compensation | 27.31M | 0.00M | -35.87M | 18.72M | 17.16M |
| Other non cash items | -990.10M | -872.85M | -567.58M | -545.62M | -603.64M |
| Free cash flow | 244.01M | 812.64M | 2184.89M | 3028.32M | 2309.01M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.01 0.03% |
33.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
0.04 0.02% |
169.25 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.90 4.50% |
20.91 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
4.03 10.61% |
42.00 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn's disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne. Further, it provides Vmonalisa, modified sodium hyaluronate filler for mid to deep dermal implantation; augentropfen stulln mono eye drops for asthenopia; EyeOP1 glaucoma treatment device; and Elcitonin for Osteoporosis pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kong Lam | Founder, Chairman, CEO & Pres | 1965 |
| Ms. Yanling Chen | CFO, VP & Exec. Director | 1970 |
| Mr. Hongbing Chen | COO, VP, Director of Sales & Marketing and Exec. Director | 1967 |
| Dr. Wai Ming Wong | Chief Technical Officer | 1961 |
| Ms. Sanyan Wu | Director of Legal Department & Company Sec. | 1983 |
| Dr. Kong Lam | Founder, Chairman, CEO & President | 1965 |
| Ms. Yanling Chen | CFO, VP & Executive Director | 1970 |
| Mr. Lieyi Ma | General Manager of the Operations & Management Center of the Group | 1970 |
| Liu Yue | Director of Investor Relations | NA |
| Ms. Sanyan Wu | Director of Legal Department & Company Secretary | 1983 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...